Clinical trials
Breast Cancer Triple Negative clinical trials
Below are recruiting breast cancer triple negative clinical trials, each written for real people, not researchers. We’re tracking 427 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06517212RecruitingPhase 2
Tirzepatide for weight loss in MRD-positive early breast cancer
This study tests whether the weight-loss drug tirzepatide (Mounjaro) can help prevent breast cancer from coming back in people who are overweight and have a sign of leftover cancer cells in their blood (called MRD-positive). You must have already finished at least one year of hormone therapy for early-stage breast cancer.
Dallas, TexasAges 18 years+ - NCT05107674RecruitingPhase 1
Early drug study for advanced cancers that have limited options
This Phase 1 study tests NX-1607 in adults with advanced cancers that are hard to treat with standard care. It focuses on safety and early signs of how well the drug may work in specific cancer types.
Duarte, CaliforniaAges 18 years+ - NCT06492759RecruitingPhase 2
High-dose radiation with pembrolizumab and chemo for pd-l1 positive tnbc
This trial tests giving high-dose radiation along with the immunotherapy drug pembrolizumab and chemo to people with a specific subtype of advanced breast cancer (PD-L1 positive triple negative). It may help shrink tumors and keep them from growing.
Atlanta, GeorgiaAges 18 years+ - NCT06471205RecruitingPhase 2
Study of BL-B01D1 plus immunotherapy for advanced triple-negative breast cancer
This study tests a new drug combination (BL-B01D1 plus an immunotherapy) for people with advanced triple-negative breast cancer who have not had prior treatment for their advanced disease. The goal is to see if the combination works better at shrinking or controlling the cancer.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06460298RecruitingPhase 1/Phase 2
ProAgio and gemcitabine for triple-negative breast cancer that has spread
This trial tests a new drug called ProAgio combined with the chemotherapy gemcitabine for people with triple-negative breast cancer that has spread to other parts of the body. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Atlanta, GeorgiaAges 18 years+ - NCT04138719RecruitingPhase 2
Test two chemotherapy combos before breast surgery for triple-negative cancer
This trial compares two different chemotherapy combinations given before surgery (neoadjuvant therapy) for people with triple-negative breast cancer. It looks to see which drug combination works better to control the cancer before and around the time of the operation.
Shijiazhuang, HebeiAges 18–70 - NCT04159142RecruitingPhase 2
Testing two chemo combos for advanced triple-negative breast cancer
This Phase 2 trial compares two chemotherapy combinations to see which works better for advanced triple-negative breast cancer. You would be asked to join one treatment arm based on study assignment and be followed for response and side effects.
Shijiazhuang, HebeiAges 18–70 - NCT06451497RecruitingPhase 1
Testing ZM008 alone and with toripalimab for advanced cancers
This trial tests a new drug called ZM008, which targets a protein on some cancer cells, first alone and then combined with another drug, toripalimab, for people with advanced solid tumors that have stopped responding to standard treatments.
Boston, MassachusettsAges 18 years+ - NCT06445738Recruiting
Can some women safely skip radiation after breast cancer surgery?
This trial is for women 50 and older with early-stage, hormone-positive or HER2-positive breast cancer. It tests whether it is safe to skip radiation therapy after a lumpectomy if an MRI before surgery shows the breast tissue looks a certain way.
San Francisco, CaliforniaAges 50 years+ - NCT06435351RecruitingEarly Phase 1
Personalized vaccine for high-risk triple-negative breast cancer
This trial tests a personalized vaccine made from your own immune cells (dendritic cells) to help prevent your high-risk triple-negative breast cancer from coming back. It is for people who had significant tumor left after standard chemotherapy and surgery.
Tampa, FloridaAges 18 years+ - NCT06422455Recruiting
Genetic testing for underserved cancer patients
This study offers free genetic testing to cancer patients and their healthcare providers. It aims to help people who may not have easy access to genetic testing understand their cancer risk.
Los Angeles, CaliforniaAges 18 years+ - NCT06434064RecruitingPhase 2
Tamoxifen and chemotherapy for triple negative breast cancer
This trial tests a combination of tamoxifen (a hormonal therapy) and pegylated liposomal doxorubicin (a type of chemotherapy) for people with triple negative breast cancer that has spread or cannot be removed by surgery. It aims to see if this combination can help people whose cancer has not responded to at least two prior treatments.
Buffalo, New YorkAges 18 years+ - NCT05329532RecruitingPhase 1/Phase 2
Modi-1 cancer vaccine for several hard-to-treat cancers
This Phase 1/2 study tests a cancer vaccine called Modi-1 Moditope in people with advanced triple-negative breast cancer, head and neck cancer, ovarian/high-grade serous cancer, or kidney cancer. It aims to help the immune system better recognize and attack the cancer.
Brighton, DefaultAges 18 years+ - NCT06393374RecruitingPhase 3
Study of a new drug combination for residual TNBC after initial treatment
This trial tests a new combination of two drugs (sacituzumab tirumotecan and pembrolizumab) compared to standard chemotherapy for people with triple-negative breast cancer that did not fully respond to initial treatment. It aims to see if this combination helps prevent cancer from coming back.
Mobile, AlabamaAges 18 years+ - NCT06365788RecruitingPhase 2
Bicalutamide and Abemaciclib for AR-positive Triple-negative Breast Cancer
This trial tests a combination of two oral drugs—bicalutamide and abemaciclib—for people with a specific type of advanced triple-negative breast cancer that grows in response to androgen hormones (AR-positive). The goal is to see if this treatment can shrink tumors or slow disease progression.
AntwerpAges 18 years+ - NCT05216432RecruitingPhase 1
RLY-2608 for PIK3CA-mutant advanced solid tumors and breast cancer
This early study (Phase 1) tests RLY-2608, a targeted cancer drug for tumors with a PIK3CA mutation. It studies the drug alone and combined with hormone therapy (and sometimes CDK4/6 or CDK4 medicines) to see safety, dose, and whether it can shrink tumors.
Tucson, ArizonaAges 18 years+ - NCT06349642Recruiting
Testing a live tumor test for immune therapy response
This trial uses a special test on live tumor samples to see if it can predict how well immune checkpoint inhibitors (a type of immunotherapy) will work for different cancers. It may help doctors choose the best treatment for you.
Phoenix, ArizonaAges 18 years+ - NCT06349512Recruiting
PET scan to predict treatment response in triple-negative breast cancer
This trial uses a special PET scan (68Ga-FAPI-46) to see if it can predict how well chemotherapy plus immunotherapy (pembrolizumab) works in people with triple-negative breast cancer before surgery. It aims to help doctors understand if the treatment is effective earlier.
AntonyAges 18 years+ - NCT06353997RecruitingPhase 2
Neoadjuvant INBRX-106 with pembrolizumab for early-stage triple-negative breast cancer
This trial tests whether adding an experimental drug called INBRX-106 to the standard immunotherapy (pembrolizumab) and chemotherapy before surgery can improve outcomes for patients with early-stage triple-negative breast cancer. The goal is to shrink the tumor and potentially reduce the risk of the cancer coming back.
Los Angeles, CaliforniaAges 18 years+ - NCT06358573RecruitingPhase 2
Injecting INT230-6 then immunochemo before surgery for early TNBC
This trial tests a two-step approach: first, an injection of the drug INT230-6 directly into the breast tumor, followed by a combination of immunotherapy and chemotherapy before surgery. The goal is to see if this sequence can shrink or eliminate the cancer more effectively, potentially allowing for a less extensive surgery.
LyonAges 18 years+ - NCT06347068RecruitingPhase 1
CAR-T cell therapy for triple-negative breast cancer
This trial tests a new treatment using your own immune cells, modified to target a protein called B7-H3 on triple-negative breast cancer cells. It may help if other treatments haven't worked.
Chapel Hill, North CarolinaAges 18 years+ - NCT06328465Recruiting
MRI for early detection of breast cancer spread
This trial is testing a new way to use MRI scans to find breast cancer that has spread to other parts of the body early. It is for people who have had aggressive breast cancer (HER2 positive or triple negative) and finished treatment with surgery, but still have a higher risk of the cancer coming back.
MilanAges 18–75 - NCT06318897RecruitingPhase 2
Immunotherapy with chemo for early triple-negative breast cancer
This trial tests a combination of an immunotherapy drug (pembrolizumab) plus two chemotherapy drugs (carboplatin and paclitaxel) given before surgery for people with early-stage, triple-negative breast cancer. The goal is to see if this treatment helps shrink or eliminate the tumor before it's removed.
Houston, TexasAges 18 years+ - NCT06324240RecruitingPhase 1
Personalized vaccine plus immunotherapy for triple-negative breast cancer
This trial tests a personalized vaccine made from your tumor combined with immunotherapy drugs (pembrolizumab or ipilimumab) for triple-negative breast cancer. It aims to help your immune system recognize and attack cancer cells.
Atlanta, GeorgiaAges 18 years+
Hear when a new Breast Cancer Triple Negative trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for breast cancer triple negative?
- Yes. Clin2 currently lists 427 recruiting breast cancer triple negative studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a breast cancer triple negative trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a breast cancer triple negative trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Breast Cancer (Triple Negative Breast Cancer (TNBC))
- Triple Negative Breast Cancer
- Breast Cancer Early Stage Breast Cancer (Stage 1-3)
- Metastatic Triple-negative Breast Cancer
- Advanced Triple Negative Breast Cancer
- Triple Negative Breast Cancer (TNBC), Early Setting
- HER2-negative Breast Cancer
- Triple Negative Breast Neoplasms
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.